Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment

American Journal of Translational Research

Volumn 4, Issue 2, 2012, Pages 206-218

  Predina, Jarrod D ^a   Judy, Brendan ^a   Kapoor, Veena ^a   Blouin, Aaron ^a   Aliperti, Louis A ^a   Levine, Daniel ^a   Fridlender, Zvi G ^a,b   Singhal, Sunil ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Concomitant immunity; Models; Perioperative immunosuppression; Recurrence; Surgery; Surgical oncology; TGF

Indexed keywords

MONOCLONAL ANTIBODY 1D11; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INOCULATION; METASTASIS; MOUSE; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE TUMOR RECURRENCE; PREOPERATIVE EVALUATION;

EID: 84860164476     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aliperti LA, Predina JD, Vachani A and Singhal S. Local and Systemic Recurrence is the Achilles Heel of Cancer Surgery. Ann Surg Oncol 2011; 18: 603-607.
2. Maruyama R, Sugio K, Mitsudomi T, Saitoh G, Ishida T and Sugimachi K. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-smallcell lung cancer. J Thorac Cardiovasc Surg 1997; 114: 535-543.
3. Fisher B. Biological research in the evolution of cancer surgery: a personal perspective. Cancer Res 2008; 68: 10007-10020.
4. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10: 972-992.
5. Davis MR, Manning LS, Whitaker D, Garlepp MJ and Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992; 52: 881-886.
6. Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R, Kopelovich L, Nakagawa H and Rustgi AK. A mouse model of human oralesophageal cancer. J Clin Invest 2002; 110: 761-769.
7. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
8. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS and Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell 2009; 16: 183-194.
9. Dasch JR, Pace DR, Waegell W, Inenaga D and Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 1989; 142: 1536-1541.
10. Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM and Berzofsky JA. Synergistic enhancement of CD8+ T cellmediated tumor vaccine efficacy by an antitransforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009; 15: 6560-6569.
11. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S and Okada H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma -associated antigen peptide vaccines. Clin Cancer Res 2009; 15: 6551-6559.
12. Tanaka T, Delong PA, Amin K, Henry A, Kruklitis R, Kapoor V, Kaiser LR and Albelda SM. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg 2005; 241: 168-178.
13. Krewet JA, Ren W, Huang XF, Chen SY and Shah MR. Anti-tumor immune responses following neoadjuvant immunotherapy with a recombinant adenovirus expressing HSP72 to rodent tumors. Cancer Immunol Immunother 2005; 54: 988-998.
14. Mukherjee S, Nelson D, Loh S, van Bruggen I, Palmer LJ, Leong C, Garlepp MJ and Robinson BW. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther 2001; 8: 580-588.
15. Jarnagin WR, Zager JS, Klimstra D, Delman KA, Malhotra S, Ebright M, Little S, DeRubertis B, Stanziale SF, Hezel M, Federoff H and Fong Y. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003; 10: 215-223.
16. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR and Albelda SM. Immunogene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004; 127: 123-130.
17. Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM and Sandler AD. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg 2006; 41: 1361-1368.
18. Kutza J, Gratz I, Afshar M and Murasko DM. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans. Anesth Analg 1997; 85: 918-923.
19. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001; Chapter 20: Unit 20 22.
20. Hill HC, Conway TF Jr, Sabel MS, Jong YS, Mathiowitz E, Bankert RB and Egilmez NK. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62: 7254-7263.
21. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5: 796-806.
22. Kishimoto H, Zhao M, Hayashi K, Urata Y, Tanaka N, Fujiwara T, Penman S and Hoffman RM. In vivo internal tumor illumination by telomerasedependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci USA 2009; 106: 14514-14517.
23. Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR and Albelda SM. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004; 10: 5907-5918.
24. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM and Ling LE. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007; 67: 2351-2359.
25. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L and Albelda SM. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68: 10247-10256.
26. Lee GT, Hong JH, Kwak C, Woo J, Liu V, Lee C and Kim IY. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line. Cancer Res 2007; 67: 6717-6724.
27. North RJ, Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells downregulate the generation of Ly-1-2+ effector T cells. J Exp Med 1984; 159: 1295-1311.
28. Bursuker I, North RJ. Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer 1986; 37: 275-281.
29. Cote AL, Usherwood EJ and Turk MJ. Tumorspecific T-cell memory: clearing the regulatory Tcell hurdle. Cancer Res 2008; 68: 1614-1617.
30. Lennard TW, Shenton BK, Borzotta A, Donnelly PK, White M, Gerrie LM, Proud G and Taylor RM. The influence of surgical operations on components of the human immune system. Br J Surg 1985; 72: 771-776.
31. Park SK, Brody JI, Wallace HA and Blakemore WS. Immunosuppressive effect of surgery. Lancet 1971; 1: 53-55.
32. Slade MS, Simmons RL, Yunis E and Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 1975; 78: 363-372.
33. Markovic SN, Knight PR and Murasko DM. Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiology 1993; 78: 700-706.
34. Akiyoshi T, Koba F, Arinaga S, Miyazaki S, Wada T and Tsuji H. Impaired production of interleukin-2 after surgery. Clin Exp Immunol 1985; 59: 45-49.
35. Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T and Kajiwara T. Suppression of cellular immunity by surgical stress. Surgery 2000; 127: 329-336.
36. Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007; 13: 6247-6251.
37. Yang L, Pang Y and Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220-227.
38. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE and Berzofsky JA. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-1752.
39. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. In vest New Drugs 2003; 21: 21-32.
40. Ruzek MC, Hawes M, Pratt B, McPherson J, Ledbetter S, Richards SM and Garman RD. Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 2003; 25: 235-257.